SF3B1 mutation
|
AML
|
SF3B1 mutation
|
AML
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
SF3B1 mutation
|
MDS
|
SF3B1 mutation
|
MDS
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
SF3B1 mutation
|
AML
|
SF3B1 mutation
|
AML
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New D)
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
SF3B1 mutation
|
MDS
|
SF3B1 mutation
|
MDS
|
luspatercept-aamt Sensitive: A2 - Guideline
|
luspatercept-aamt Sensitive: A2 - Guideline
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
ofatumumab Resistant: B - Late Trials
|
ofatumumab Resistant: B - Late Trials
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
chlorambucil Resistant: B - Late Trials
|
chlorambucil Resistant: B - Late Trials
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
obinutuzumab Resistant: B - Late Trials
|
obinutuzumab Resistant: B - Late Trials
|
SF3B1 mutation
|
AML
|
SF3B1 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials
|
SF3B1 mutation
|
MDS
|
SF3B1 mutation
|
MDS
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
SF3B1 mutation
|
AML
|
SF3B1 mutation
|
AML
|
venetoclax + ABBV 075 Sensitive: C3 – Early Trials
|
venetoclax + ABBV 075 Sensitive: C3 – Early Trials
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
|
SF3B1 mutation
|
CML
|
SF3B1 mutation
|
CML
|
VE-821 Sensitive: D – Preclinical
|
VE-821 Sensitive: D – Preclinical
|